This panel at the Community Oncology Alliance conference discussed the impact of PBM response to the end of direct and indirect remuneration (DIR) fees, which has been dramatic cuts to cancer drug reimbursement.
A lawsuit that followed a health system revoking community oncologists' hospital privileges was the jumping off point for a discussion of how to manage this key relationship.
/PRNewswire/ PatientPoint® today announced the addition of Jeffrey Vacirca, MD, FACP, and Amy Grogg, PharmD, to its board of directors. Dr. Vacirca will.
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 BriaCell Therapeutics Corp. , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer.
Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All.